Clinical Trials Browser

Phase 2 × Docetaxel × Breast × Clear all

NCT04329065 2026-05-19

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

Phase 2 Recruiting

Anatomic Stage I Breast Cancer AJCC v8

NCT04001829 2026-05-15

Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer

Phase 2 Active not recruiting

249 enrolled 14 charts

Anatomic Stage I Breast Cancer AJCC v8

NCT06618014 2026-05-15

NeoTOP

Phase 2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06445400 2026-05-13

A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

Phase 2 Active not recruiting

HER2-positive Breast Cancer

NCT07220135 2026-05-06

NeoTHERa

Phase 2 Recruiting

Breast Neoplasms

NCT04266249 2026-05-05

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Phase 2 Active not recruiting

Anatomic Stage II Breast Cancer AJCC v8

NCT07102381 2026-04-29

EmpowHER 208

Phase 2 Recruiting

Breast Neoplasms

NCT05645380 2026-04-28

NeoTRACT

Phase 2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07402473 2026-04-23

EUREKA

Phase 2 Recruiting

HER2-positive Early-stage Breast Cancer

NCT07545044 2026-04-22

A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer

Phase 2 Not yet recruiting

Breast Neoplasms

NCT06042569 2026-04-17

Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial

Phase 2 Recruiting

Anatomic Stage I Breast Cancer AJCC v8

NCT07527806 2026-04-17

Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07017673 2026-04-02

Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT07335081 2026-03-24

ctDNA in HER2+ EBC Neoadjuvant Treatment

Phase 2 Recruiting

Breast Neoplasms

NCT01658462 2026-03-16

VAROCE

Phase 2 Completed

Breast Neoplasms

NCT04293393 2026-03-12

CARABELA

Phase 2 Active not recruiting

200 enrolled 27 charts

Breast Neoplasms

NCT07421141 2026-02-27

Opti-HER2

Phase 2 Active not recruiting

Breast Neoplasms

NCT07423611 2026-02-20

RACE

Phase 2 Not yet recruiting

Breast Neoplasms

NCT06291064 2026-02-17

TARMAC

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT06348134 2026-02-17

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Phase 2 Recruiting

Breast Neoplasms

NCT04095689 2026-01-23

INTEGRAL

Phase 2 Terminated

8 enrolled 10 charts

Triple Negative Breast Neoplasms

NCT03879577 2026-01-21

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

Phase 2 Active not recruiting

53 enrolled 13 charts

Breast Neoplasms

NCT04872985 2026-01-06

Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT06107673 2025-12-11

Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）

Phase 2 Recruiting

Breast Neoplasms

NCT06409390 2025-12-04

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT07246317 2025-11-28

Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer

Phase 2 Not yet recruiting

Breast Neoplasms

NCT04419181 2025-10-14

Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

Phase 2 Withdrawn

HER2-positive Breast Cancer

NCT00295893 2025-09-25

Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer

Phase 2 Active not recruiting

121 enrolled 10 charts

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT05900206 2025-09-02

ARIADNE

Phase 2 Recruiting

Breast Neoplasms

NCT07136974 2025-08-22

Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.

Phase 2 Not yet recruiting

Breast Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT07116824 2025-08-12

HB1801 Combined Treatment of HER2-positive Breast Cancer

Phase 2 Not yet recruiting

HER2-positive Breast Cancer

NCT07083505 2025-07-24

A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer

Phase 2 Not yet recruiting

Advanced Breast Cancer

NCT06441890 2025-07-14

BRE-10

Phase 2 Recruiting

Breast Neoplasms

NCT06439693 2025-06-26

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT06927180 2025-06-23

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms

NCT03161353 2025-04-23

PHERGain

Phase 2 Active not recruiting

Breast Neoplasms

NCT01396655 2025-04-17

DA-PET

Phase 2 Completed

Breast Neoplasms

NCT02547987 2025-03-12

CADENCE

Phase 2 Active not recruiting

25 enrolled 9 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02488564 2025-02-03

met-HEReMYTA

Phase 2 Completed

HER-2 Positive Breast Cancer

NCT05475678 2025-01-23

Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02299999 2025-01-15

SAFIR02_Breast

Phase 2 Active not recruiting

Breast Neoplasms

NCT02339532 2024-11-08

NeoTOP

Phase 2 Completed

Breast Neoplasms

NCT03839823 2024-10-09

RIGHT Choice

Phase 2 Completed

222 enrolled 17 charts

Breast Neoplasms

NCT06470633 2024-06-24

To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer

Phase 2 Not yet recruiting

Breast Neoplasms

NCT03887130 2024-04-30

Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer

Phase 2 Completed

152 enrolled 14 charts

Breast Neoplasms

NCT03639948 2024-04-11

NeoPACT

Phase 2 Unknown

120 enrolled 12 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00712881 2024-02-23

Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer

Phase 2 Completed

126 enrolled 16 charts

Breast Neoplasms

NCT06254690 2024-02-12

The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study

Phase 2 Recruiting

Breast Neoplasms

NCT03742986 2023-12-19

Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)

Phase 2 Completed

8 enrolled 10 charts

Breast Neoplasms